A Study to Investigate Multiple Sclerosis Relapse Prevention With mRNA-1195 Compared With Placebo in Participants Aged 18 to ≤55 Years
Conditions
Multiple Sclerosis
Simple summaryAI-assisted
This summary is produced by a language model and is experimental. It may be incomplete or inaccurate and is not a substitute for professional medical advice.
Locations
Boston Clinical Trials Inc - Internal Medicine, Boston, Massachusetts, United States
Quest Research Institute, Farmington Hills, Michigan, United States
Sharlin Health & Neurology, Ozark, Missouri, United States
Washington University School of Medicine Neurology Clinical Unit, St Louis, Missouri, United States
Oklahoma Medical Research Foundation (OMRF) MS Center of Excellence, Oklahoma City, Oklahoma, United States
University of Texas Southwestern Medical Center, Dallas, Texas, United States
ANESC Research, El Paso, Texas, United States
Contact: Principal Investigator (Aamr Herekar, MD)Saturn Research Solutions, Plano, Texas, United States
University of the Sunshine Coast Clinical Trials, Birtinya, Queensland, Australia
North Bristol NHS Trust - Southmead Hospital, Bristol, United Kingdom
Cardiff and Vale University Health Board - University Hospital Wales, Cardiff, United Kingdom
Anne Rowling Regenerative Neurology Clinic, University of Edinburgh, Edinburgh, United Kingdom
NHS Greater Glasgow & Clyde - Institute of Neurological Sciences, Glasgow, United Kingdom
Cambridge Clinical Research Centre, London, United Kingdom
East Kent Hospitals University NHS Foundation Trust, London, United Kingdom
The Newcastle Upon Tyne Hospitals NHS Foundation Trust, Newcastle upon Tyne, United Kingdom
Sheffield Teaching Hospital NHS foundation Trust, Herries Road, Sheffield, United Kingdom